Primecap Management Co. CA Has $53.58 Million Stake in Sanofi (NASDAQ:SNY)

Primecap Management Co. CA decreased its position in shares of Sanofi (NASDAQ:SNY) by 0.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,110,928 shares of the company’s stock after selling 5,070 shares during the quarter. Primecap Management Co. CA’s holdings in Sanofi were worth $53,580,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after purchasing an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors boosted its stake in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after buying an additional 751 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after buying an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the last quarter. Finally, Kentucky Trust Co bought a new stake in shares of Sanofi in the 4th quarter worth approximately $436,000. 14.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on SNY shares. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Sanofi currently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $59.11 on Wednesday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The company has a 50 day simple moving average of $54.03 and a two-hundred day simple moving average of $52.85. The company has a market capitalization of $150.01 billion, a price-to-earnings ratio of 23.74, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.